Skip to main content

Table 3 Characteristics of patients with rheumatoid arthritis with and without Mycobacterium avium complex pulmonary disease

From: Diagnostic performance of measuring antibodies to the glycopeptidolipid core antigen specific to Mycobacterium avium complex in patients with rheumatoid arthritis: results from a cross-sectional observational study

Variable Overall (n = 369) RA with MAC-PD (n = 10) RA without MAC-PD (n = 359) P valuea
Age (yr) 64.3 ± 13.0 72.2 ± 6.1 64.1 ± 13.1 0.065
Female sex (%) 80.8 80.0 81.2 0.95
BMI (kg/m2) 21.8 ± 1.9 19.2 ± 2.3 21.8 ± 3.5 0.020
RA disease duration (yr) 13.0 ± 3.4 21.0 ± 4.7 11.2 ± 3.4 0.028
Current smoking (%) 11.0 0 11.4 0.26
RF positivity (%) 83.8 90.0 83.5 0.60
Steinbrocker stage III or IV (%)b 63.6 80.0 61.2 0.24
Steinbrocker class 3 or 4 (%)b 12.5 0 13.1 0.22
DAS28-CRP 2.8 ± 1.3 3.0 ± 0.8 2.8 ± 1.7 0.48
Peripheral blood lymphocytes (count/μl) 1736 ± 26.1 1322 ± 23.6 1740 ± 25.5 0.044
Oral corticosteroid use (%) 30.0 30.0 29.0 0.95
Prednisolone dosage (mg/day) 3.2 ± 1.4 3.7 ± 1.2 3.1 ± 1.5 0.56
MTX use (%) 66.7 60.0 67.4 0.62
MTX dosage (mg/wk) 7.5 ± 1.6 5.7 ± 1.5 7.6 ± 2.6 0.075
Use of immunosuppressive drugs, except for MTX (%)c 8.2 10.0 7.2 0.74
Use of biologic DMARDs (%) 52.9 60.0 52.4 0.65
Duration of biologic DMARD use (yr) NA 4.2 ± 2.6 4.0 ± 2.8 0.87
Diabetes mellitus (%) 9.8 20.0 8.9 0.23
  1. Abbreviations: BMI body mass index, DAS28-CRP Disease Activity Score in 28 joints using C-reactive protein level, DMARD disease-modifying antirheumatic drug, MAC-PD Mycobacterium avium complex pulmonary disease, MTX methotrexate, NA not applicable, RA rheumatoid arthritis, RF rheumatoid factor
  2. Values are the percentage or mean ± standard deviation unless otherwise indicated. Bold values indicate significant differences (P < 0.05)
  3. aBetween patients with RA with and without MAC-PD
  4. bSteinbrocker et al. classification system [20] was used to define RA disease stages and classes
  5. cImmunosuppressive drugs included tacrolimus, leflunomide, and mizoribine